JP7740715B2 - ペプチドおよびそれを含む複合体 - Google Patents

ペプチドおよびそれを含む複合体

Info

Publication number
JP7740715B2
JP7740715B2 JP2022535021A JP2022535021A JP7740715B2 JP 7740715 B2 JP7740715 B2 JP 7740715B2 JP 2022535021 A JP2022535021 A JP 2022535021A JP 2022535021 A JP2022535021 A JP 2022535021A JP 7740715 B2 JP7740715 B2 JP 7740715B2
Authority
JP
Japan
Prior art keywords
group
residue
amino acid
arg
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022535021A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022009698A1 (enExample
JPWO2022009698A5 (enExample
Inventor
良雄 林
健太郎 高山
敦彦 谷口
洋一 根岸
史子 伊東
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tokyo University of Pharmacy and Life Sciences
Original Assignee
Tokyo University of Pharmacy and Life Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tokyo University of Pharmacy and Life Sciences filed Critical Tokyo University of Pharmacy and Life Sciences
Publication of JPWO2022009698A1 publication Critical patent/JPWO2022009698A1/ja
Publication of JPWO2022009698A5 publication Critical patent/JPWO2022009698A5/ja
Application granted granted Critical
Publication of JP7740715B2 publication Critical patent/JP7740715B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2022535021A 2020-07-06 2021-06-25 ペプチドおよびそれを含む複合体 Active JP7740715B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020116583 2020-07-06
JP2020116583 2020-07-06
PCT/JP2021/024125 WO2022009698A1 (ja) 2020-07-06 2021-06-25 ペプチドおよびそれを含む複合体

Publications (3)

Publication Number Publication Date
JPWO2022009698A1 JPWO2022009698A1 (enExample) 2022-01-13
JPWO2022009698A5 JPWO2022009698A5 (enExample) 2024-07-02
JP7740715B2 true JP7740715B2 (ja) 2025-09-17

Family

ID=79553070

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022535021A Active JP7740715B2 (ja) 2020-07-06 2021-06-25 ペプチドおよびそれを含む複合体

Country Status (2)

Country Link
JP (1) JP7740715B2 (enExample)
WO (1) WO2022009698A1 (enExample)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009539357A (ja) 2006-06-06 2009-11-19 ヘルムホルツ−ツェントルム フュア インフェクツィオンスフォルシュンク ゲーエムベーハー リウマチ熱関連ペプチド（ｐａｒｆ）および診断マーカーとしてのその使用
WO2014119753A1 (ja) 2013-01-31 2014-08-07 学校法人 東京薬科大学 マイオスタチン阻害ペプチド
JP2016523274A (ja) 2013-06-26 2016-08-08 ザイジェン インフラメーション リミテッド 種々の疾患を処置するためのｊｎｋシグナル伝達経路の新規の細胞透過性ペプチド阻害剤の使用
JP2017528417A (ja) 2014-06-12 2017-09-28 ザ ユニヴァーシティ オブ バース 薬物送達強化剤
WO2018030432A1 (ja) 2016-08-10 2018-02-15 学校法人東京薬科大学 ペプチドもしくはその薬学的に許容される塩、またはそれらのプロドラッグ
JP2020059663A (ja) 2018-10-09 2020-04-16 学校法人東京薬科大学 ペプチドもしくはその薬学的に許容される塩、またはそれらのプロドラッグ

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009539357A (ja) 2006-06-06 2009-11-19 ヘルムホルツ−ツェントルム フュア インフェクツィオンスフォルシュンク ゲーエムベーハー リウマチ熱関連ペプチド（ｐａｒｆ）および診断マーカーとしてのその使用
WO2014119753A1 (ja) 2013-01-31 2014-08-07 学校法人 東京薬科大学 マイオスタチン阻害ペプチド
JP2016523274A (ja) 2013-06-26 2016-08-08 ザイジェン インフラメーション リミテッド 種々の疾患を処置するためのｊｎｋシグナル伝達経路の新規の細胞透過性ペプチド阻害剤の使用
JP2017528417A (ja) 2014-06-12 2017-09-28 ザ ユニヴァーシティ オブ バース 薬物送達強化剤
WO2018030432A1 (ja) 2016-08-10 2018-02-15 学校法人東京薬科大学 ペプチドもしくはその薬学的に許容される塩、またはそれらのプロドラッグ
JP2020059663A (ja) 2018-10-09 2020-04-16 学校法人東京薬科大学 ペプチドもしくはその薬学的に許容される塩、またはそれらのプロドラッグ

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
OKAMOTO, Hideyuki et al.，Inactivation of myostatin by photo-oxygenation using catalyst-functionalized peptides，Chem. Commun.，2019年，Vol.55，pp.9108-9111
TAKAYAMA, Kentaro et al.，Chain-Shortened Myostatin Inhibitory Peptides Improve Grip Strength in Mice，ACS Med. Chem. Lett.，2019年，Vol.10，pp.985-990

Also Published As

Publication number Publication date
JPWO2022009698A1 (enExample) 2022-01-13
WO2022009698A1 (ja) 2022-01-13

Similar Documents

Publication Publication Date Title
JP5686825B2 (ja) メタスチン誘導体およびその用途
EP3059244B1 (en) C-met protein agonist
US20040023859A1 (en) Melanocortin receptor ligands
JP2010265271A (ja) ソマトスタチンベクター
JP2016065018A (ja) Ｃｘｃｒ７結合剤およびｃｘｃｒ７結合剤を含有する医薬組成物
SK286581B6 (sk) Deriváty dolastatinu 15, farmaceutický prípravok s ich obsahom a ich použitie
EA020613B1 (ru) Цитотоксические конъюгаты с соединением, связывающим рецептор нейропептида y
RU2430107C2 (ru) Производные метастина и их применение
JPWO2009131191A1 (ja) メタスチン誘導体およびその用途
US20040122013A1 (en) Analogs of nocicettin
CN101516404A (zh) 喜树碱-细胞渗透肽缀合物和含有其的药物组合物
JP6952320B2 (ja) 新規ｎｋ３受容体アゴニスト
JP7740715B2 (ja) ペプチドおよびそれを含む複合体
JP7032808B2 (ja) ペプチドもしくはその薬学的に許容される塩、またはそれらのプロドラッグ
US10562935B2 (en) Stapled peptides and uses thereof
JP2020059663A (ja) ペプチドもしくはその薬学的に許容される塩、またはそれらのプロドラッグ
JP7181550B2 (ja) ペプチド、その薬学的に許容される塩、またはそれらのプロドラッグ、およびそれらの用途
WO2014119753A4 (ja) マイオスタチン阻害ペプチド
US9815867B2 (en) Peptide for inhibiting vascular endothelial growth factor receptor
JP7201967B2 (ja) ペプチドもしくはその薬学的に許容される塩、またはそれらのプロドラッグ
CN116390742A (zh) 环状趋化素-9衍生物
EP4501941A1 (en) Peptide complex having trkb binding activity
CN120265645A (zh) EphA2结合待审肽及包含其的组合物
RU2454425C2 (ru) Производные метастина и их применение
WO2011088462A2 (en) Alpha-fetoprotein 'ring and tail' peptides

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A5211

Effective date: 20221213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240624

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250709

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250805

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250828

R150 Certificate of patent or registration of utility model

Ref document number: 7740715

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150